Antibe Therapeutics announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched Neomem FlexPlus, a high-performance barrier membrane for regenerative procedures in oral surgery.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. 

Neomem FlexPlus is a single layer collagen membrane derived from porcine peritoneum. Suture pull-out testing has shown this membrane to be biomechanically strong yet conformability evaluations demonstrate the ability to adapt to the contour of the surgical site. Neomem FlexPlus can be placed wet or dry in situ and it hydrates quickly, providing handling characteristics that make surgical placement easy.

Test data and clinical experience suggest that Neomem FlexPlus outperforms a leading barrier membrane in four metrics, specifically strength, handling, resorption and tissue response.

“The launch of Neomem FlexPlus provides Citagenix with its strongest barrier membrane yet, and a direct competitor to the leading product in the market,” said Antibe’s CEO Dan Legault.